AIOM 2022 - XXIV National Congress of Italian Association of Medical Oncology
Nov 05 - Nov 07, 2022 | RomeItaly
LARVOL is not affiliated with XXIV National Congress of Italian Association of Medical Oncology and all trademarks, logos, and brand names are property of their respective owners
Showing 32 abstracts linked to Trials
DURABILITY OF EFFICACY WITH SELPERCATINIB IN PATIENTS (PTS) WITH RET FUSION+ NON-SMALL-CELL LUNG CANCER (NSCLC)
CABOZANTINIB (C) PLUS ATEZOLIZUMAB (A) AS A FIRST- OR SECOND-LINE THERAPY FOR PATIENTS (PTS) WITH ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) AND PREVIOUSLY-TREATED EGFR MUTANT ANSCLC
SARS-COV-2 OMICRON (B.1.1.529) VARIANT INFECTION LEADS TO HIGH MORBIDITY AND MORTALITY IN UNVACCINATED PATIENTS WITH CANCER
TUMOUR-AGNOSTIC INDICATIONS: ARE WE MOVING TOWARDS A MUTATION-DRIVEN APPROACH IN PRECISION ONCOLOGY?
MODIFIED FOLFOXIRI PLUS PANITUMUMAB (MFOLFOXIRI/PAN) VERSUS MFOLFOX6/PAN AS INITIAL TREATMENT OF UNRESECTABLE RAS/BRAF WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC) PATIENTS: RESULTS OF THE PHASE III RANDOMIZED TRIPLETE STUDY BY GONO
FIRST LINE AVELUMAB IN PD-L1+VE METASTATIC OR LOCALLY ADVANCED UROTHELIAL CANCER (AUC) PATIENTS UNFIT FOR CISPLATIN (CIS): THE ARIES TRIAL
THE HOBOE MULTICENTER RANDOMIZED PHASE 3 TRIAL IN PREMENOPAUSAL PATIENTS (PTS) WITH HORMONERECEPTOR POSITIVE EARLY BREAST CANCER (EBC) COMPARING TRIPTORELIN PLUS EITHER TAMOXIFEN (T) OR LETROZOLE (L) OR ZOLEDRONIC ACID + LETROZOLE (ZL): 8YR EFFICACY ANALYSIS
IMPACT OF TP53 MUTATIONS IN ROS1 POSITIVE NSCLC RECEIVING LORLATINIB: FINAL RESULTS OF THE PFROST TRIAL
CABINMET: CABOZANTINIB IN MET DEREGULATED NON-SMALL CELL LUNG CANCER (NSCLC) PATIENTS
MOLECULAR PREDICTORS OF IMMUNOTHERAPY EFFICACY IN LUNG SQUAMOUS-CELL CARCINOMA (LSCC): RESULTS FROM THE RANDOMIZED PROSPECTIVE SQUINT TRIAL
RATIONALE AND DESIGN OF A SINGLE-ARM, PHASE 2, MULTI-CENTER STUDY OF CHEMOIMMUNOTHERAPY FOLLOWED BY HYPOFRACTIONATED RT AND MAINTENANCE IMMUNOTHERAPY IN PATIENTS WITH UNRESECTABLE STAGE III NSCLC: THE DEDALUS TRIAL
CRIZOTINIB IN ROS1+ NSCLC: LONG-TERM OUTCOME OF PATIENTS WITH BRAIN METASTASES INCLUDED IN THE PHASE II METROS TRIAL
SAFETY OF SUNITINIB IN PATIENTS WITH TYPE B3 THYMOMA OR THYMIC CARCINOMA IN THE STYLE TRIAL
CRIZOTINIB IN ANAPLASTIC LYMPHOMA KINASE (ALK) REARRANGED NON-SMALLCELL LUNG CANCER (NSCLC): REAL WORLD DATA FROM THE ITALIAN SPECIALK TRIAL
FOLFOXIRI/BEVACIZUMAB (BEV) COMBINED WITH NIVOLUMAB (NIV) AS FIRST-LINE (1L) THERAPY IN METASTATIC COLORECTAL CANCER (MCRC) PATIENTS (PTS) WITH RAS/BRAF MUTATIONS, REGARDLESS OF MICROSATELLITE STATUS: RESULTS OF PHASE II NIVACOR TRIAL (GOIRC-03-2018)